Mobia Medical's recent S-1/A filing on May 4, 2026, setting IPO terms at $14–$16 per share for 10 million shares—implying a roughly $500 million fully diluted market cap—has left trader consensus razor-thin across outcomes, reflecting uncertainty in debut pricing and day-one performance for its FDA-approved Vivistim paired vagus nerve stimulation platform. The neurostimulation device's clinical edge as the sole randomized-trial-validated therapy for chronic ischemic stroke motor recovery, backed by $32 million in 2025 revenue from over 1,000 implants, competes against reimbursement hurdles like case-by-case Medicare coverage sans national policy and insurer classifications as experimental, alongside ongoing losses and scaling risks in the $30 billion market. Pricing this week could swing sentiment amid choppy medtech IPO dynamics.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$500M–$700M 47%
<$500M 23%
$700M–$900M 15%
$900M+ 15%
NEW
NEW
May 8, 2026
<$500M
23%
$500M–$700M
47%
$700M–$900M
15%
$900M+
15%
No IPO before July 2026
6%
$500M–$700M 47%
<$500M 23%
$700M–$900M 15%
$900M+ 15%
NEW
NEW
May 8, 2026
<$500M
$70 Vol.
23%
$500M–$700M
$1,819 Vol.
47%
$700M–$900M
$26 Vol.
15%
$900M+
$138 Vol.
15%
No IPO before July 2026
$0 Vol.
6%
This market will resolve based on Mobia Medical's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Mobia Medical's recent S-1/A filing on May 4, 2026, setting IPO terms at $14–$16 per share for 10 million shares—implying a roughly $500 million fully diluted market cap—has left trader consensus razor-thin across outcomes, reflecting uncertainty in debut pricing and day-one performance for its FDA-approved Vivistim paired vagus nerve stimulation platform. The neurostimulation device's clinical edge as the sole randomized-trial-validated therapy for chronic ischemic stroke motor recovery, backed by $32 million in 2025 revenue from over 1,000 implants, competes against reimbursement hurdles like case-by-case Medicare coverage sans national policy and insurer classifications as experimental, alongside ongoing losses and scaling risks in the $30 billion market. Pricing this week could swing sentiment amid choppy medtech IPO dynamics.
This market will resolve based on Mobia Medical's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Market Opened: May 5, 2026, 7:06 PM ET
Volume
$2,053End Date
May 8, 2026Market Opened
May 5, 2026, 7:06 PM ETResolver
0x69c47De9D...This market will resolve based on Mobia Medical's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Mobia Medical's recent S-1/A filing on May 4, 2026, setting IPO terms at $14–$16 per share for 10 million shares—implying a roughly $500 million fully diluted market cap—has left trader consensus razor-thin across outcomes, reflecting uncertainty in debut pricing and day-one performance for its FDA-approved Vivistim paired vagus nerve stimulation platform. The neurostimulation device's clinical edge as the sole randomized-trial-validated therapy for chronic ischemic stroke motor recovery, backed by $32 million in 2025 revenue from over 1,000 implants, competes against reimbursement hurdles like case-by-case Medicare coverage sans national policy and insurer classifications as experimental, alongside ongoing losses and scaling risks in the $30 billion market. Pricing this week could swing sentiment amid choppy medtech IPO dynamics.
This market will resolve based on Mobia Medical's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$2,053End Date
May 8, 2026Market Opened
May 5, 2026, 7:06 PM ETResolver
0x69c47De9D...Mobia Medical's recent S-1/A filing on May 4, 2026, setting IPO terms at $14–$16 per share for 10 million shares—implying a roughly $500 million fully diluted market cap—has left trader consensus razor-thin across outcomes, reflecting uncertainty in debut pricing and day-one performance for its FDA-approved Vivistim paired vagus nerve stimulation platform. The neurostimulation device's clinical edge as the sole randomized-trial-validated therapy for chronic ischemic stroke motor recovery, backed by $32 million in 2025 revenue from over 1,000 implants, competes against reimbursement hurdles like case-by-case Medicare coverage sans national policy and insurer classifications as experimental, alongside ongoing losses and scaling risks in the $30 billion market. Pricing this week could swing sentiment amid choppy medtech IPO dynamics.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions